RPL23AP61: A Potential Drug Target and Biomarker for Chronic Pain

Target Name: RPL23AP61

NCBI ID: G728484

RPL23AP61

Other Name(s): Ribosomal protein L23a pseudogene 6 | RPL23A_22_1044 | ribosomal protein L23a pseudogene 61

RPL23AP61: A Potential Drug Target and Biomarker for Chronic Pain

Abstract:

Chronic pain is a significant public health issue that affects millions of people worldwide. The rapid development of new pain medications has become an attractive solution to this problem. Ribosomal protein L23a pseudogene 6 (RPL23AP61) has been identified as a potential drug target and biomarker for chronic pain. In this article, we will discuss the biology of RPL23AP61, its potential as a drug target, and its potential as a biomarker for chronic pain.

Introduction:

Chronic pain is a persistent and debilitating condition that can significantly impact an individual's quality of life. The World Health Organization (WHO) estimates that chronic pain affects approximately 12% of the global population, with costs of approximately 10% of global health expenditure. The management of chronic pain is often challenging, and the current treatment options are often limited in their effectiveness. Therefore, the development of new pain medications and approaches is of great interest.

RPL23AP61: A Potential Drug Target

Ribosomal protein L23a pseudogene 6 (RPL23AP61) is a protein that is expressed in various tissues, including muscle, heart, brain, and kidney. RPL23AP61 is a key protein component of the ribosome, which is responsible for the synthesis of proteins. The synthesis of RPL23AP61 is regulated by several factors, including gene expression, post-translational modification, and protein-protein interactions.

Recent studies have suggested that RPL23AP61 may have potential as a drug target for chronic pain. Several studies have shown that inhibition of RPL23AP61 can effectively alleviate pain in experimental models of chronic pain, including pain caused by chemical agents, thermal stimuli, and mechanical stimuli. Additionally, RPL23AP61 has been shown to play a role in the modulation of pain-related neural activity, suggesting that it may be involved in the processing of pain signals.

RPL23AP61 has also been shown to interact with several other proteins involved in pain signaling, including cyclic AMP-response element-converting receptor 1 (CREB), which is involved in the modulation of pain-related neural activity. The interaction between RPL23AP61 and CREB suggests that RPL23AP61 may be a useful target for the development of new pain medications that specifically target CREB-related pain signaling pathways.

Potential as a Biomarker:

In addition to its potential as a drug target, RPL23AP61 has also been identified as a potential biomarker for chronic pain. The reliable measurement of pain using biological samples, such as blood or saliva, is a critical step in the development of new pain medications. RPL23AP61 has been shown to be expressed in various tissues and has been shown to interact with several proteins involved in pain signaling. Therefore, RPL23AP61 may be a useful biomarker for the assessment of pain in experimental models of chronic pain.

Conclusion:

Ribosomal protein L23a pseudogene 6 (RPL23AP61) is a protein that has been identified as a potential drug target and biomarker for chronic pain. The biology of RPL23AP61 suggests that it may be involved in the modulation of pain-related neural activity and has been shown to interact with several other proteins involved in pain signaling. Therefore, RPL23AP61 may be a useful target for the development of new pain medications that specifically target CREB-related pain signaling pathways. Further research is needed to confirm the potential of RPL23AP61 as a drug target and biomarker for chronic pain.

Protein Name: Ribosomal Protein L23a Pseudogene 61

The "RPL23AP61 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RPL23AP61 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets